A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
Active Not Recruiting
This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS co-administered (bivalent delivery) against a matching placebo arm. Bivalent GI.1 and GII.4 vaccines are being investigated for the prevention of noroviral gastroenteritis caused by norovirus GI.1 and GII.4.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/20/2024
Locations: Ark Clinical Research, Long Beach, California
Conditions: Norovirus Infections
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: VA Loma Linda Healthcare System, Loma Linda, California +4 locations
Conditions: Heart Failure, Myocardial Infarction
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
Completed
The purpose of this study is to determine if 2 doses of Pneumococcal Conjugate Vaccine (PCV) followed by 1 dose of Pneumococcal Polysaccharide Vaccine (PPV) in HIV-infected children on anti-HIV therapy is helpful and safe in fighting pneumococcal infections in this group of children. This study will also look at the protection provided by childhood vaccination against measles, pertussis, and hepatitis B virus. Pneumococcal infections are the most common AIDS-related infection in HIV-infected ch... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
10/28/2021
Locations: Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California +4 locations
Conditions: HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
Completed
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/28/2021
Locations: Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California +7 locations
Conditions: HIV Infections, Influenza
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
Completed
The purpose of this study is to determine immune system function following vaccination in HIV-infected children currently taking anti-HIV drugs. To test the effectiveness of prior vaccination, patients in this study will receive booster shots of one of two pneumococcal vaccines, a hepatitis B vaccine, and a measles vaccine.
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
10/28/2021
Locations: Usc La Nichd Crs, Alhambra, California +2 locations
Conditions: HIV Infections
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Completed
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
Gender:
ALL
Ages:
Between 6 months and 24 months
Trial Updated:
07/19/2021
Locations: University of California, UC San Diego CRS, La Jolla, California +1 locations
Conditions: Respiratory Syncytial Virus Infections
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: Clinical Office - Jason Cuellar M.D., Beverly Hills, California +23 locations
Conditions: Staphylococcal Vaccine
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
Completed
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Gender:
FEMALE
Ages:
Between 10 years and 17 years
Trial Updated:
01/03/2019
Locations: GSK Investigational Site, Beverly Hills, California +3 locations
Conditions: Herpes Simplex
HerpeVac Trial for Young Women
Completed
The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evalua... Read More
Gender:
FEMALE
Ages:
Between 18 years and 30 years
Trial Updated:
07/26/2018
Locations: GSK Investigational Site, Carson, California +7 locations
Conditions: Herpes Simplex Infection
Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
Completed
To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to \< 48 months of age
Gender:
ALL
Ages:
Between 6 months and 48 months
Trial Updated:
06/11/2018
Locations: Site 112, Long Beach, California +3 locations
Conditions: Influenza
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Completed
This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts. This Protocol Posting has been updated following Amendment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2018
Locations: GSK Investigational Site, Long Beach, California +1 locations
Conditions: Herpes Zoster
Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children
Completed
Human parainfluenza virus type 3 (HPIV3) is a major cause of pneumonia and other respiratory diseases in infants and children. This study will evaluate the safety and immune response of an HPIV3 vaccine in infants and young children.
Gender:
ALL
Ages:
Between 6 months and 36 months
Trial Updated:
12/02/2014
Locations: Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California +1 locations
Conditions: Parainfluenza Virus 3, Human